JRC-LAMP-vax vaccine: Phase I started

Immunomic began an open-label, U.S. Phase I trial to evaluate 2 or 4 mg intramuscular JRC-LAMP-vax vaccine given on days 0, 14, 28 and 42 in about 42 Japanese ex-patriates previously exposed to Japane...